EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring

Sara Bønløkke iD, Magnus Stougaard, Boe Sandahl Sorensen, Erik Parner, Gitte-Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakær, Jesper Bertelsen, Katrine Fuglsang, Torben Steiniche

Cancer · 2026

DOI: 10.1002/cncr.70282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Sara Bønløkke und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, DNA, Viral, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KV Fonden, Søster og Verner Lipperts fond, IMK Almene Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating cell‐free human papillomavirus (ccfHPV) DNA is a promising biomarker for cervical cancer monitoring. This study used next‐generation sequencing (NGS) to assess its prognostic and surveillance value.

Methods

The authors included 141 cervical cancer patients (International Federation of Gynecology and Obstetrics IA1–IVB) grouped by treatment: primary surgery ( n = 50), primary surgery + adjuvant oncological ( n = 22), and primary oncological treatment ( n = 69). Plasma was collected pretreatment, at early follow‐up (first post‐treatment sample [FPS]), and during longer follow‐up. ccfHPV DNA was detected using an NGS‐based assay, enabling high sensitivity without prior knowledge of human papillomavirus (HPV) genotype. Associations between ccfHPV DNA status and recurrence were assessed using Cox proportional hazards models, and predictive accuracy was evaluated via sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).

Results

Pretreatment ccfHPV DNA positivity was detected in 8.0%, 36.4%, and 82.6% of patients across the groups, and ccfHPV DNA positivity was significantly associated with higher recurrence risk (adjusted hazard ratio [HR], 4.92; 95% confidence interval [CI], 1.29–18.7; p = .02). At FPS, ccfHPV DNA positivity strongly predicted recurrence (adjusted HR, 19.1; 95% CI, 7.27–50.2), with a PPV of 83% and NPV of 90% for recurrence within 50 months. Among patients who developed recurrence, ccfHPV DNA was detectable before clinical evidence of recurrence in 60.9% of cases with a mean lead time of 144 days. Conclusion ccfHPV DNA detected by NGS is a strong prognostic biomarker for residual disease or recurrence. Its strong performance, already at early follow‐up, supports its integration into individualized follow‐up strategies. Prospective multicenter studies should validate these findings and guide clinical implementation. Trial Registration The study was registered with ClinicalTrials.gov (identifiers: NCT03749720)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsNeoplasm Recurrence, LocalDNA, ViralHigh-Throughput Nucleotide SequencingPapillomavirus InfectionsHuman Papillomavirus VirusesHumansFemaleMiddle AgedAdultPrognosisAgedBiomarkers, TumorSensitivity and Specificity

Stichwörter der Autor:innen

HPVbiomarkerccfDNAcervical cancercirculating HPV DNAnext‐generation sequencingpost‐treatment monitoring

Substanzen

DNA, ViralBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Obstetrics and Gynecology, Gødstrup Regional Hospital, Herning, Denmark.
  • Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Public Health, Unit for Biostatistics, Aarhus University, Aarhus, Denmark.
  • Department of Oncology, Odense University Hospital, Odense C, Denmark.

ORCID-Profile: Sara Bønløkke

Förderung

  • KV Fonden
  • Søster og Verner Lipperts fond
  • IMK Almene Fond
  • Civilingeniør Frode V. Nyegaard og Hustrus Fond
  • Fabrikant Einar Willumsens Mindelegat
  • Folketingsmand J. Christensen og hustru K. Christensens Fond
  • Grosserer A.V. Lykfeldt og Hustrus Legat
  • Harboefonden

Zitieren

APA

Bønløkke, S., Stougaard, M., Sorensen, B. S., Parner, E., Nyvang, G. B., Lindegaard, J. C., Blaakær, J., Bertelsen, J., Fuglsang, K., & Steiniche, T. (2026). Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring. Cancer. https://doi.org/10.1002/cncr.70282

Vancouver

Bønløkke S, Stougaard M, Sorensen BS, Parner E, Nyvang GB, Lindegaard JC, et al. Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring. Cancer. 2026. doi:10.1002/cncr.70282

BibTeX
@article{Bnlkke2026,
  author = {Bønløkke, Sara and Stougaard, Magnus and Sorensen, Boe Sandahl and Parner, Erik and Nyvang, Gitte-Bettina and Lindegaard, Jacob Christian and Blaakær, Jan and Bertelsen, Jesper and Fuglsang, Katrine and Steiniche, Torben},
  title = {Ultrasensitive next‐generation sequencing–based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70282}
}
Kostenlos starten →